These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19276281)

  • 1. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence.
    Redmond AM; Bane FT; Stafford AT; McIlroy M; Dillon MF; Crotty TB; Hill AD; Young LS
    Clin Cancer Res; 2009 Mar; 15(6):2098-106. PubMed ID: 19276281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
    J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
    Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
    Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.
    Karmakar S; Foster EA; Smith CL
    Endocrinology; 2009 Apr; 150(4):1588-96. PubMed ID: 19095746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
    Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-alpha interaction with the CREB binding protein coactivator is regulated by the cellular environment.
    Jaber BM; Mukopadhyay R; Smith CL
    J Mol Endocrinol; 2004 Feb; 32(1):307-23. PubMed ID: 14766010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.
    Dutertre M; Smith CL
    Mol Endocrinol; 2003 Jul; 17(7):1296-314. PubMed ID: 12714702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
    Yamashita H; Takahashi S; Ito Y; Yamashita T; Ando Y; Toyama T; Sugiura H; Yoshimoto N; Kobayashi S; Fujii Y; Iwase H
    Cancer Sci; 2009 Nov; 100(11):2028-33. PubMed ID: 19659610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.
    Fleming FJ; Myers E; Kelly G; Crotty TB; McDermott EW; O'Higgins NJ; Hill AD; Young LS
    J Clin Pathol; 2004 Oct; 57(10):1069-74. PubMed ID: 15452162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
    Karmakar S; Foster EA; Blackmore JK; Smith CL
    Endocr Relat Cancer; 2011 Feb; 18(1):113-27. PubMed ID: 21059860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    J Clin Pathol; 2007 Apr; 60(4):397-404. PubMed ID: 16775123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
    Alkner S; Jensen MB; Rasmussen BB; Bendahl PO; Fernö M; Rydén L; Mouridsen H;
    Breast Cancer Res Treat; 2017 Nov; 166(2):481-490. PubMed ID: 28766132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12.
    Kishimoto H; Wang Z; Bhat-Nakshatri P; Chang D; Clarke R; Nakshatri H
    Carcinogenesis; 2005 Oct; 26(10):1706-15. PubMed ID: 15917309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.
    Myers E; Fleming FJ; Crotty TB; Kelly G; McDermott EW; O'higgins NJ; Hill AD; Young LS
    Br J Cancer; 2004 Nov; 91(9):1687-93. PubMed ID: 15477868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
    Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
    Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators.
    Weldon CB; Elliott S; Zhu Y; Clayton JL; Curiel TJ; Jaffe BM; Burow ME
    Surgery; 2004 Aug; 136(2):346-54. PubMed ID: 15300201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.